市場調查報告書

酸性神經磷脂酶缺損症(ASMD):市場洞察,流行病學,市場預測 2028年

Acid sphingomyelinase deficiency (ASMD) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 911508
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
酸性神經磷脂酶缺損症(ASMD):市場洞察,流行病學,市場預測 2028年 Acid sphingomyelinase deficiency (ASMD) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

新興10個國家(土耳其、俄羅斯、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷、中國、台灣)的2017年酸性神經磷脂酶缺損症(ASMD)的患病人數估算為8,799人,以及市場規模估算為120萬美元。

本報告提供新興10個國家(土耳其、俄羅斯、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷、中國、台灣)的酸性神經磷脂酶缺損症(ASMD)市場調查,市場及疾病概要,各表現型、臨床症狀、各國流行病學的預測,未滿足需求,新藥概要,以整體及各國的市場規模的變化與預測,市場成長要素及障礙分析等資料彙整。

目錄

第1章 重要洞察

第2章 酸性神經磷脂酶缺損症(ASMD)概要

  • 分佈情形(成果值)
  • 分佈情形(預測值)

第3章 疾病背景和概要

  • 簡介
  • 歷史
  • 各病型
    • NPD-A(尼曼匹克症 A型)
    • NPD-B(尼曼匹克症 B型)
  • 病因
  • 症狀
  • 病理生理學
  • 診斷
  • 生物標記

第4章 流行病學和患者人口

  • 主要調查結果
  • 關鍵意見領袖的意見

第5章 新興10個國家的酸性神經磷脂酶缺損症(ASMD)的總罹患數

  • 總患病數
  • 診斷患病數

第6章 酸性神經磷脂酶缺損症(ASMD)的各國流行病學

  • 假設和理論的根據
  • 中國
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 台灣
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀
  • 沙烏地阿拉伯
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀
  • 阿拉伯聯合大公國
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀
  • 俄羅斯
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀
  • 土耳其
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀
  • 墨西哥
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀
  • 巴西
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀
  • 阿根廷
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀
  • 哥倫比亞
    • 總患病數
    • 診斷數量
    • 診斷數量:各臨床表現型
    • 診斷數量:各臨床症狀

第7章 酸性神經磷脂酶缺損症(ASMD)的治療和管理

第8章 未滿足需求

第9章 新藥

  • Olipudase Alfa:Sanofi
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 優點與缺點
    • 產品簡介

第10章 酸性神經磷脂酶缺損症(ASMD):新興國家分析

  • 主要調查結果
  • 關鍵意見領袖的意見
  • 新興國家(10個國家)的市場規模
    • 市場規模:各治療藥物

第11章 市場預測:各國

  • 新興市場:市場預測
  • 中國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 台灣
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 俄羅斯
  • 土耳其
  • 墨西哥
  • 巴西
  • 阿根廷
  • 哥倫比亞

第12章 市場成長要素

第13章 市場障礙

第14章 附錄

  • 報告方法

第15章 DelveInsight的服務內容

第16章 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0674

DelveInsight's "Acid sphingomyelinase deficiency (ASMD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acid sphingomyelinase deficiency (ASMD), historical and forecasted epidemiology as well as the Acid sphingomyelinase deficiency (ASMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acid sphingomyelinase deficiency (ASMD) market report provides current treatment practices, emerging drugs, Acid sphingomyelinase deficiency (ASMD) market share of the individual therapies, current and forecasted Acid sphingomyelinase deficiency (ASMD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acid sphingomyelinase deficiency (ASMD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acid sphingomyelinase deficiency (ASMD) Disease Understanding and Treatment Algorithm

The DelveInsight Acid sphingomyelinase deficiency (ASMD) market report gives a thorough understanding of the Acid sphingomyelinase deficiency (ASMD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Acid sphingomyelinase deficiency (ASMD).

Treatment

It covers the details of conventional and current medical therapies available in the Acid sphingomyelinase deficiency (ASMD) market for the treatment of the condition. It also provides Acid sphingomyelinase deficiency (ASMD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Acid sphingomyelinase deficiency (ASMD) Epidemiology

The Acid sphingomyelinase deficiency (ASMD) epidemiology division provide insights about historical and current Acid sphingomyelinase deficiency (ASMD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acid sphingomyelinase deficiency (ASMD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Acid sphingomyelinase deficiency (ASMD) Epidemiology

The epidemiology segment also provides the Acid sphingomyelinase deficiency (ASMD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Acid sphingomyelinase deficiency (ASMD) Drug Chapters

Drug chapter segment of the Acid sphingomyelinase deficiency (ASMD) report encloses the detailed analysis of Acid sphingomyelinase deficiency (ASMD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Acid sphingomyelinase deficiency (ASMD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Acid sphingomyelinase deficiency (ASMD) treatment.

Acid sphingomyelinase deficiency (ASMD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Acid sphingomyelinase deficiency (ASMD) treatment.

Acid sphingomyelinase deficiency (ASMD) Market Outlook

The Acid sphingomyelinase deficiency (ASMD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Acid sphingomyelinase deficiency (ASMD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Acid sphingomyelinase deficiency (ASMD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Acid sphingomyelinase deficiency (ASMD) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Acid sphingomyelinase deficiency (ASMD) market in 7MM.

The United States Market Outlook

This section provides the total Acid sphingomyelinase deficiency (ASMD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Acid sphingomyelinase deficiency (ASMD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Acid sphingomyelinase deficiency (ASMD) market size and market size by therapies in Japan is also mentioned.

Acid sphingomyelinase deficiency (ASMD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Acid sphingomyelinase deficiency (ASMD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acid sphingomyelinase deficiency (ASMD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acid sphingomyelinase deficiency (ASMD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acid sphingomyelinase deficiency (ASMD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Acid sphingomyelinase deficiency (ASMD) emerging therapies.

Reimbursement Scenario in Acid sphingomyelinase deficiency (ASMD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Acid sphingomyelinase deficiency (ASMD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Acid sphingomyelinase deficiency (ASMD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Acid sphingomyelinase deficiency (ASMD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Acid sphingomyelinase deficiency (ASMD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Acid sphingomyelinase deficiency (ASMD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acid sphingomyelinase deficiency (ASMD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Acid sphingomyelinase deficiency (ASMD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acid sphingomyelinase deficiency (ASMD) market

Report Highlights

  • In the coming years, Acid sphingomyelinase deficiency (ASMD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acid sphingomyelinase deficiency (ASMD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Acid sphingomyelinase deficiency (ASMD). Launch of emerging therapies will significantly impact the Acid sphingomyelinase deficiency (ASMD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acid sphingomyelinase deficiency (ASMD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acid sphingomyelinase deficiency (ASMD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acid sphingomyelinase deficiency (ASMD) Pipeline Analysis
  • Acid sphingomyelinase deficiency (ASMD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acid sphingomyelinase deficiency (ASMD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Acid sphingomyelinase deficiency (ASMD) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Acid sphingomyelinase deficiency (ASMD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Acid sphingomyelinase deficiency (ASMD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Acid sphingomyelinase deficiency (ASMD) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Acid sphingomyelinase deficiency (ASMD) market size during the forecast period (2017-2030)?
  • At what CAGR, the Acid sphingomyelinase deficiency (ASMD) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Acid sphingomyelinase deficiency (ASMD) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Acid sphingomyelinase deficiency (ASMD) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Acid sphingomyelinase deficiency (ASMD)?
  • What is the historical Acid sphingomyelinase deficiency (ASMD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Acid sphingomyelinase deficiency (ASMD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acid sphingomyelinase deficiency (ASMD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Acid sphingomyelinase deficiency (ASMD) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Acid sphingomyelinase deficiency (ASMD) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Acid sphingomyelinase deficiency (ASMD) in the USA, Europe, and Japan?
  • What are the Acid sphingomyelinase deficiency (ASMD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acid sphingomyelinase deficiency (ASMD)?
  • How many therapies are developed by each company for Acid sphingomyelinase deficiency (ASMD) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Acid sphingomyelinase deficiency (ASMD) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Acid sphingomyelinase deficiency (ASMD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acid sphingomyelinase deficiency (ASMD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Acid sphingomyelinase deficiency (ASMD)?
  • What are the global historical and forecasted market of Acid sphingomyelinase deficiency (ASMD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Acid sphingomyelinase deficiency (ASMD) market
  • To understand the future market competition in the Acid sphingomyelinase deficiency (ASMD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acid sphingomyelinase deficiency (ASMD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Acid sphingomyelinase deficiency (ASMD) market
  • To understand the future market competition in the Acid sphingomyelinase deficiency (ASMD) market

Table of Contents

1. Key Insights

2. Executive Summary of Acid sphingomyelinase deficiency (ASMD)

3. Competitive Intelligence Analysis for Acid sphingomyelinase deficiency (ASMD)

4. Acid sphingomyelinase deficiency (ASMD): Market Overview at a Glance

  • 4.1. Acid sphingomyelinase deficiency (ASMD) Total Market Share (%) Distribution in 2017
  • 4.2. Acid sphingomyelinase deficiency (ASMD) Total Market Share (%) Distribution in 2030

5. Acid sphingomyelinase deficiency (ASMD): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Acid sphingomyelinase deficiency (ASMD) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Acid sphingomyelinase deficiency (ASMD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Acid sphingomyelinase deficiency (ASMD) Treatment and Management
  • 8.2. Acid sphingomyelinase deficiency (ASMD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Acid sphingomyelinase deficiency (ASMD) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Acid sphingomyelinase deficiency (ASMD): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Acid sphingomyelinase deficiency (ASMD) Market Size in 7MM
  • 13.3. Acid sphingomyelinase deficiency (ASMD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Acid sphingomyelinase deficiency (ASMD) Total Market Size in the United States
    • 15.1.2. Acid sphingomyelinase deficiency (ASMD) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Acid sphingomyelinase deficiency (ASMD) Total Market Size in Germany
    • 15.3.2. Acid sphingomyelinase deficiency (ASMD) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Acid sphingomyelinase deficiency (ASMD) Total Market Size in France
    • 15.4.2. Acid sphingomyelinase deficiency (ASMD) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Acid sphingomyelinase deficiency (ASMD) Total Market Size in Italy
    • 15.5.2. Acid sphingomyelinase deficiency (ASMD) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Acid sphingomyelinase deficiency (ASMD) Total Market Size in Spain
    • 15.6.2. Acid sphingomyelinase deficiency (ASMD) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Acid sphingomyelinase deficiency (ASMD) Total Market Size in the United Kingdom
    • 15.7.2. Acid sphingomyelinase deficiency (ASMD) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Acid sphingomyelinase deficiency (ASMD) Total Market Size in Japan
    • 15.8.3. Acid sphingomyelinase deficiency (ASMD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Acid sphingomyelinase deficiency (ASMD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Acid sphingomyelinase deficiency (ASMD) Epidemiology (2017-2030)
  • Table 2 : 7MM Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in Germany (2017-2030)
  • Table 6 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in France (2017-2030)
  • Table 8 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in Italy (2017-2030)
  • Table 10 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in Spain (2017-2030)
  • Table 12 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in the UK (2017-2030)
  • Table 14 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in Japan (2017-2030)
  • Table 16 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Acid sphingomyelinase deficiency (ASMD) Epidemiology (2017-2030)
  • Figure 2 : 7MM Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in the United States (2017-2030)
  • Figure 4 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in Germany (2017-2030)
  • Figure 6 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in France (2017-2030)
  • Figure 8 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in Italy (2017-2030)
  • Figure 10 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in Spain (2017-2030)
  • Figure 12 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in the UK (2017-2030)
  • Figure 14 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Acid sphingomyelinase deficiency (ASMD) Epidemiology in Japan (2017-2030)
  • Figure 16 : Acid sphingomyelinase deficiency (ASMD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)